IngredientesCitrus sinensis, comúnmente conocida como naranja dulce, es una especie de cítrico ampliamente cultivada, valorada por su fruto jugoso, su cáscara aromática y sus numerosos compuestos que apoyan la salud. Cuando se etiqueta como "Citrus sinensis (propietario)", generalmente se refiere a un extracto estandarizado o mezcla especializada desarrollada a partir de la cáscara, la pulpa o el fruto entero de la naranja dulce, a menudo concentrado para obtener compuestos bioactivos específicos como flavonoides, polifenoles, aceites esenciales o pectina.
Los extractos propietarios de Citrus sinensis pueden formularse para suministrar dosis concentradas de compuestos como hesperidina, narirutina, naringenina y limonoides cítricos, conocidos por sus beneficios antioxidantes, antiinflamatorios, vasoprotectores y metabólicos. Algunas versiones también destacan la auraptenina cítrica y los flavones polimetoxilados (PMFs), que han demostrado en investigaciones apoyar el equilibrio del colesterol, la función hepática y la regulación celular saludable.
Dependiendo de la formulación, los extractos propietarios de Citrus sinensis pueden utilizarse para apoyar:
Algunas versiones propietarias también pueden incluir aceite de naranja prensado en frío u otros fitocompuestos para efectos digestivos y de mejora del estado de ánimo, utilizados frecuentemente en alimentos funcionales, suplementos para el alivio del estrés y mezclas metabólicas.
Uso Histórico
La naranja dulce (Citrus sinensis) tiene una historia larga y bien documentada tanto en tradiciones culinarias como medicinales. Aunque es originaria del Sudeste Asiático, se extendió por todo el Medio Oriente y el Mediterráneo a través de rutas comerciales y se convirtió en un cultivo de fruta básico en Europa en el siglo XV. Los médicos árabes fueron de los primeros en describir sus usos medicinales en detalle, recomendando la cáscara y el jugo para las náuseas, la indigestión, las palpitaciones cardíacas y la melancolía.
En la Medicina Tradicional China, la cáscara de naranja (a menudo denominada chen pi) se utiliza para regular el qi, fortalecer la digestión y reducir la flema, lo que indica su uso histórico tanto para afecciones digestivas como respiratorias. La cáscara blanca interior (albedo) y las membranas —ricas en flavonoides— también se usaban para enfriar el calor interno y apoyar la desintoxicación hepática.
El aceite esencial de la cáscara de naranja dulce ha sido utilizado durante mucho tiempo en aromaterapia para calmar los nervios, elevar el estado de ánimo y reducir el estrés, lo que refleja una profunda tradición popular de uso de los cítricos para la armonía emocional y digestiva.
En la era moderna, las formas estandarizadas y propietarias de Citrus sinensis han surgido como ingredientes específicos en alimentos funcionales, nutracéuticos y preparaciones farmacéuticas, particularmente para el apoyo vascular, metabólico y relacionado con el estado de ánimo. Estas innovaciones preservan las aplicaciones tradicionales de salud de la naranja dulce mientras mejoran la potencia y la biodisponibilidad a través de métodos de extracción y concentración.
Condiciones de salud que Bifidobacterium lactis puede ayudar a apoyar.
Bifidobacterium lactis (animalis subsp. lactis) has demonstrated efficacy in reducing abdominal pain and IBS symptom severity in a large RCT. UABla-12 (1×10^10 CFU/day for 6 weeks) significantly improved IBS Symptom Severity Scale scores including abdominal pain subscores compared to placebo.
Clinical trials and narrative reviews support that Bifidobacterium lactis strains can reduce allergic rhinitis symptoms by modulating the Th1/Th2 immune balance and lowering serum IgE and IL-13. A randomized double-blind trial of B. lactis A6 in adults with perennial allergic rhinitis demonstrated significant symptom reduction. The gut-lung axis provides the mechanistic basis for systemic effects on airway allergy.
Preclinical studies show B. lactis strains reduce ovalbumin-induced allergic asthma markers in mice, including IgE, airway inflammation, and Th2 cytokines, partly through tryptophan metabolism. Human evidence is limited to indirect support from respiratory allergy trials; dedicated clinical asthma RCTs are lacking.
A crossover RCT of B. lactis TISTR 2591 in T2DM patients significantly attenuated fasting glucose elevation and improved HOMA-IR versus placebo. B. lactis HN019 in metabolic syndrome patients showed favorable trends in glucose metabolism. Evidence supports modest glycemic benefits as adjunctive therapy.
Bifidobacterium lactis NLS-SS was studied in a 2013 double-blind RCT in active celiac disease patients. A 2025 RCT in 85 CeD patients used B. lactis CCT 7858 with L. rhamnosus for 90 days, concluding probiotics are beneficial adjunct therapy for CeD symptom relief. A 2008 study demonstrated B. lactis inhibits the toxic effects of wheat gliadin in epithelial cell cultures.
Bifidobacterium lactis (also known as B. animalis subsp. lactis) has been studied in infants and children for allergy prevention and treatment. RCTs have found that supplementation with Lactobacillus rhamnosus HN001 and B. lactis HN019 perinatally reduced prevalence of early atopic dermatitis, with specific Toll-like receptor genetic variations associated with protection. It is also an ingredient in specialized infant formulas studied for atopic dermatitis reduction.
Bifidobacterium lactis (B. animalis subsp. lactis) is one of the most widely studied probiotic strains in pediatric medicine, evaluated in clinical trials for diarrhea, NEC, H. pylori eradication-associated diarrhea, and gut tolerance in infants. It is a common addition to infant formulas and pediatric probiotic supplements with substantial safety data.
Bifidobacterium lactis (animalis subsp. lactis) is among the most clinically validated probiotic strains for children's immune and respiratory health. A 2025 double-blind RCT in 120 children with recurrent RTIs found Bifidobacterium animalis subsp. lactis XLTG11 plus Lactiplantibacillus plantarum significantly reduced frequency and duration of respiratory infections, fever, cough, and pneumonia versus placebo. It strongly enhances secretory IgA levels.
B. lactis HN019 reduced total cholesterol and LDL-C in a randomized trial in metabolic syndrome patients. A meta-analysis of Bifidobacterium-containing probiotics in 24 RCTs found significant reductions in total cholesterol, LDL-C, and triglycerides. Results in normocholesterolemic individuals are less consistent.
A randomized trial of B. lactis HN019 in metabolic syndrome patients demonstrated significant reductions in TNF-α and IL-6 compared to baseline and control. A meta-analysis of Bifidobacterium-containing probiotic RCTs found significant reductions in hs-CRP, TNF-α, and IL-6. B. lactis strains also restored gut barrier integrity in preclinical models, reducing inflammatory signaling.
B. lactis BB-12 has been investigated in randomized trials for its effect on cold/flu incidence and severity in healthy adults; B. lactis Bl-04 significantly reduced the risk of upper respiratory illness in a large RCT. A pediatric RCT with a mixture including B. lactis HN019 shortened fever duration by approximately 2 days. Cochrane review evidence includes B. lactis strains for prevention of URTIs.
Bifidobacterium lactis BB-12 (Bifidobacterium animalis subsp. lactis) has been evaluated in dedicated double-blind RCTs for infantile colic with positive results. An 80-infant RCT found that B. lactis BB-12 at 10^9 CFU/day significantly reduced daily crying duration versus placebo starting from the second week. It is also incorporated in 2'-FL-supplemented formula studies for fussiness.
Bifidobacterium lactis (animalis subsp. lactis) has been specifically tested in a randomized, double-blind, placebo-controlled trial for collagenous colitis in combination with Lactobacillus acidophilus. It is among the most widely used Bifidobacteria strains in IBD probiotic research and multi-strain formulations for UC.
Bifidobacterium lactis (Bifidobacterium animalis subsp. lactis) is the single probiotic strain with the strongest individual evidence for improving stool frequency in chronic constipation. A 2022 systematic review of 30 RCTs identified B. lactis as the only individual strain achieving statistical significance for stool frequency improvement. Multiple dedicated RCTs with strains HN019 and UABla-12 confirm this finding.
Bifidobacterium lactis has clinical evidence for reducing acute infectious diarrhea duration in children. A Bayesian network meta-analysis of 84 RCTs (13,443 children) found it reduced diarrhea duration by approximately 0.98 days versus placebo (moderate GRADE certainty). It is also documented in Cochrane reviews of antibiotic-associated diarrhea prevention in children.
Bifidobacterium lactis (animalis subsp. lactis) has been studied in multiple RCTs for eczema prevention in high-risk infants and SCORAD reduction in children with atopic dermatitis. A 2019 RCT found a mixture of L. rhamnosus and B. animalis subsp. lactis reduced eczema incidence in infants over 6 months.
Bifidobacterium lactis is identified as a histamine-degrading probiotic strain relevant to histamine intolerance and food sensitivity management. It is among the probiotics that can degrade biogenic amines including histamine in the gut. Multiple reviews recognize its role in supporting gut microbiota diversity and reducing food-allergy-related atopic outcomes.
B. animalis subsp. lactis Bi-07 has been shown in two clinical trials and an EFSA review to support lactose digestion in individuals with lactose maldigestion, via β-galactosidase (lactase) activity. The strain was found to be superior to placebo and in one trial non-inferior to lactase supplementation for lactose digestion.
Bifidobacterium lactis is used in combination probiotic formulations shown in clinical trials to improve H. pylori eradication rates and reduce gastric mucosal inflammation. A prospective trial combining B. lactis with L. acidophilus, Lactiplantibacillus plantarum, and S. boulardii found improved H. pylori eradication and fewer adverse effects.
Bifidobacterium lactis is one of the most commercially studied probiotic species, with strong clinical evidence for modulating gut microbiota composition, improving stool consistency, enhancing intestinal barrier integrity, and reducing gut dysbiosis across multiple populations and conditions.
Bifidobacterium lactis is widely studied for gut health and has documented effects on the gut-brain axis through SCFA production, gut barrier enhancement, and immune modulation. Clinical fMRI evidence shows fermented milk products containing B. lactis strains reduce emotional brain activation. It is a common component of multi-strain psychobiotic formulations.
B. lactis HN019 significantly reduced BMI in a randomized trial in metabolic syndrome patients. Broader evidence from Bifidobacterium meta-analyses supports modest effects on adiposity in obese or metabolically compromised individuals, linked to shifts in gut microbiota composition and SCFA-mediated energy regulation.
Multiple RCTs have tested B. lactis strains in IBS patients. B. lactis BI040 in a 12-week RCT reduced pain frequency and intensity, while B. lactis UABla-12 improved abdominal pain severity. Meta-analyses of Bifidobacterium strains in IBS show limited but significant benefits over placebo, primarily for pain and global symptoms.
Bifidobacterium lactis is a well-studied probiotic strain with clinical evidence in UC, where it has been used in both standalone and combination probiotic formulations demonstrating improved clinical and endoscopic outcomes in IBD trials.
B. lactis TISTR 2591 improved HOMA-IR and enhanced β-cell function (HOMA-β) in a crossover RCT of T2DM patients. The proposed mechanism involves SCFA production, reduced gut permeability, and modulation of the inflammatory milieu that underlies insulin resistance.
Bifidobacterium lactis (Bi-07 strain) has the highest documented β-galactosidase activity among tested probiotic strains and was superior to placebo in two crossover RCTs for lactose intolerance. Multiple studies and a meta-analysis confirm its efficacy for reducing breath hydrogen and LI symptoms. It is one of the most-evidenced probiotic strains for this condition.
Bifidobacterium lactis (also designated B. animalis subsp. lactis) consistently appears in systematic reviews as one of the most effective probiotic strains for reducing intestinal permeability. It has been documented to restore intestinal barrier function in IBS, obese adults, and colon cancer patients in multiple high-quality clinical studies. A systematic review (ScienceDirect, 2023) identified Bifidobacterium, including B. lactis, as among the most common effective genera in positive clinical trials.
A randomized trial of B. lactis HN019 in 51 metabolic syndrome patients found significant reductions in BMI, total cholesterol, LDL, TNF-α, and IL-6 after 45 days. B. lactis strains thus address multiple components of MetS—dyslipidemia, inflammation, and central obesity—simultaneously.
Bifidobacterium lactis (including strains BB-12 and HN019) has been studied in multiple RCTs and in vitro for effects on the oral microbiome and periodontal health. BB-12 combined with L. rhamnosus GG altered oral microbiota in a 4-week RCT. B. lactis HN019 showed antimicrobial activity against P. gingivalis, P. intermedia, F. nucleatum, and A. actinomycetemcomitans in vitro and improved gingival inflammation in periodontitis patients.
Bifidobacterium lactis (B. animalis subsp. lactis, particularly strain BB-12) is one of the most widely used probiotic strains in pregnancy research. In a landmark Finnish RCT, formulations including B. lactis BB-12 significantly reduced GDM incidence (13% vs. 36%, p=0.003). It has also demonstrated improved neonatal gut colonization and reduced infantile atopic disease in multiple RCTs.
An exploratory RCT demonstrated that B. lactis NCC2818 mitigated immune parameters and allergic symptoms during seasonal grass-pollen exposure. The strain reduced markers of Th2 immune activation during the allergy season. Results are preliminary, warranting larger confirmatory trials.
A meta-analysis of Bifidobacterium-containing probiotic RCTs showed significant triglyceride reductions. B. lactis HN019 demonstrated favorable effects on blood lipids in metabolic syndrome patients. Effects appear more robust in individuals with pre-existing hypertriglyceridemia than in healthy normolipidemic individuals.
Multiple clinical trials, including a large RCT with B. lactis Bl-04 and combination trials with B. lactis BB-12 and HN019, demonstrate that B. lactis supplementation reduces the risk, duration, or severity of upper respiratory tract infections. Effects are linked to enhanced NK-cell function, secretory IgA, and mucosal immunity.
Bifidobacterium lactis was a component of the multi-strain probiotic in the 18-month double-blind RCT (181 children with febrile UTI) that achieved UTI-free survival in 96.7% vs. 83.3% placebo (p=0.02). It supports urinary flora through gut-urinary axis mechanisms — reducing the intestinal uropathogen reservoir and modulating immune responses relevant to urinary tract defense.
B. lactis strains enhance innate antiviral defenses by stimulating NK-cell activity and T-cell responses, and by elevating secretory IgA at mucosal surfaces. Clinical trial data show reduced viral URTI risk and improved immune cell function following B. lactis supplementation.
Sistemas corporales que Bifidobacterium lactis puede ayudar a apoyar.
Volver